Trastuzumab or Lapatinib with Neoadjuvant Chemotherapy in the Management of Previously Untreated HER2-Positive Primary Breast Cancer


Trastuzumab or Lapatinib with Neoadjuvant Chemotherapy in the Management of Previously Untreated HER2-Positive Primary Breast Cancer
Slides from a presentation at SABCS 2010 and transcribed comments from a recent interview
with Michael Untch, MD, PhD (12/11/10)

Untch M et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy: Primary efficacy endpoint analysis of the GEPARQUINTO study (GBG 44). San Antonio Breast Cancer Symposium 2010;Abstract S3-1.

Prof Untch is Head of the Clinic for Gynecology and the Breast Cancer Center of HELIOS Klinikum Berlin-Buch at the Academic Hospital of the University Charité in Berlin, Germany.